MEDIA ABOUT US
18.04
2018
7th Conference "CePT - a platform for the development of innovative biomedicine 2018"
   
12.04
2018
Oncology: the company will present the research results at the AACR
21.03
2018
A big appetite for ambitious novelties
     
01.03
2018
An innovative drug for breast cancer?
   
13.02
2018
Changes in Helix Immuno-Oncology.
07.02
2018
Helix Immuno-Oncology to present its research results in Chicago
   
17.10
2017
The FDA accelerates work on a clinical trial of L-DOS47
     
21.09
2017
Poland must seize the opportunity in the field of biotechnology.
   
31.08
2017
The R&D results concerning the V-DOS47 molecule published in “Frontiers in Immunology”
   
31.08
2017
Research results of V-DOS47 in “Frontiers in Immunology”
   
29.06
2017
Helix Immuno-Oncology conducts research on new cancer treatment strategies
   
15.05
2017
The Polish company is working on a technology that may become a breakthrough in the treatment of solid tumors. Among others lung, breast or pancreatic cancer
   
20.04
2017
Tumour Defence Breaker DOS-47 technology breaks the cancer defence barriers
        
19.04
2017
Effective therapy for solid tumors ... soon available in Poland?
   
14.04
2017
The Polish biotechnology company presented the clinical trial results of the L-DOS47 molecule in non-small cell lung cancer
   
29.03
2017
Helix Immuno-Oncology: DOS47 (Tumour Defence Breaker)
   
25.01
2017
More effective fight against cancer
   
18.01
2017
Expanding access to immunotherapy of cancers
20.12
2016
Innovative anti-cancer therapy tested in Poland
01.12
2016
Tumor Defence Breaker – a breakthrough in the treatment of solid tumors?
   
« Poprzednia | 1 2 | Następna »